Skip to main content
SpringerLink
Log in

Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Respiratory tract infections (RTIs), the most common indication for outpatient antimicrobial therapy, impose a heavy medical and societal burden and present a difficult therapeutic challenge in the face of increasing pathogen resistance worldwide. Gatifloxacin is a new broad-spectrum fluoroquinolone with excellent activity against prevalent respiratory bacteria, including penicillin-resistantStreptococcus pneumoniae and atypical pathogens. A multicenter, open-label, noncomparative surveillance study carried out in Mexico evaluated the safety and efficacy of oral gatifloxacin 400 mg once daily in 17,923 adult outpatients with community-acquired pneumonia (CAP) (n=3322), acute exacerbations of chronic bronchitis (AECB) (n=5885), and acute bacterial sinusitis (n=8716). Voluntary, unpaid physician participation contributed to an unbiased study design. Physician-assessed global rate of cure or improvement was 96.3%; efficacy was 95.8% in CAP, 96.1% in AECB, and 96.4% in sinusitis. The incidences of relapse (1.5%) and therapeutic failure (0.7%) were low. The most commonly reported adverse events, nausea (2.76%), headache (2.20%), and dizziness (1.33%), were generally mild and self-limited. Oral gatifloxacin 400 mg once daily is effective and safe for patients with CAP, AECB, and acute sinusitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ober NS. Respiratory tract infections: consider the total cost of care.Drug Benefit Trends. 1998; 10:23–29.

    Google Scholar 

  2. Acute respiratory infections: the forgotten pandemic.WHO Bull. 1998;76:101–103.

    Google Scholar 

  3. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy.Am Rev Respir Dis. 1993;148:1418–1426.

    PubMed  CAS  Google Scholar 

  4. Bartlett JG, Mundy LM. Community-acquired pneumonia.N Engl J Med. 1995;333:1618–1624.

    Article  PubMed  CAS  Google Scholar 

  5. King DE, Pippin HJ Jr. Community-acquired pneumonia in adults: initial antibiotic therapy.Am Fam Physician. 1997;56:544–550.

    PubMed  CAS  Google Scholar 

  6. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Guidelines from the Infectious Diseases Society of America. Community-acquired pneumonia in adults: guidelines for management.Clin Infect Dis. 1998;26:811–838.

    Article  PubMed  CAS  Google Scholar 

  7. Leiner S. Acute bronchitis in adults: commonly diagnosed but poorly defined.Nurse Pract. 1997; 22:104–117.

    Article  PubMed  CAS  Google Scholar 

  8. Ball P, Make B. Acute exacerbations of chronic bronchitis. An international comparison.Chest. 1998;113(3 suppl):199S-204S.

    Article  PubMed  CAS  Google Scholar 

  9. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis.Chest. 2000;117(5 suppl 2): 380S-385S.

    Article  PubMed  CAS  Google Scholar 

  10. Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Bennett JE, Dolin R, eds.Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill Livingstone; 2000:706–710.

    Google Scholar 

  11. Read RC. Infection in acute exacerbations of chronic bronchitis: a clinical perspective.Respir Med. 1999;93:845–850.

    Article  PubMed  CAS  Google Scholar 

  12. Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis.Semin Respir Infect. 2000;15:59–70.

    Article  PubMed  CAS  Google Scholar 

  13. Chester AC. Chronic sinusitis.Am Fam Physician. 1996;53:877–887.

    PubMed  CAS  Google Scholar 

  14. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial sinusitis.Otolaryngol Head Neck Surg. 2000;123:S1-S32.

    Google Scholar 

  15. Sener B, Hascelik G, Onerci M, Tunckanat F. Evaluation of the microbiology of chronic sinusitis.J Laryngol Otol. 1996;110:547–550.

    Article  PubMed  CAS  Google Scholar 

  16. Hoban DJ, Fluitt AC, Roussel-Delvallez M, Doern GV, Jones RN, The Sentry Participants Group. Three year global experience of the SENTRY Antimicrobial Surveillance Program (1997–1999) monitoring community-acquired respiratory tract infection (CARTI) pathogens: results from 17,166 strains ofS. pneumoniae, H. influenzae, andM. catarrhalis. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto, Ontario, Canada. Abstract 1220.

  17. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D.In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.J Antimicrob Chemother. 2000;45:437–446.

    Article  PubMed  CAS  Google Scholar 

  18. Hershberger E, Rybak MJ. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistantStreptococcus pneumoniae in an in vitro infection model.Antimicrob Agents Chemother. 2000;44:598–601.

    Article  PubMed  CAS  Google Scholar 

  19. LaCreta FP, Kaul S, Kollia GD, Duncan G, Randall DM, Grasela DM. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults.Pharmacotherapy. 2000;20(6 pt 2): 59S-66S.

    Article  PubMed  CAS  Google Scholar 

  20. Lubasch A, Keller I, Borner K, Koeppe P, Lode H.Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.Antimicrob Agents Chemother. 2000;44:2600–2603.

    Article  PubMed  CAS  Google Scholar 

  21. Jones RN, Pfaller MA, Wikler M, Nicholson S. Clinical efficacy and safety of gatifloxacin inS. pneumoniae community-acquired pneumonia: initial report from TeqCES. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto, Ontario, Canada. Abstract 817.

  22. Talan DA. New concepts in antimicrobial therapy for emergency department infections.Ann Emerg Med. 1999;34:503–516.

    Article  PubMed  CAS  Google Scholar 

  23. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new ‘respiratory quinolones.’J Antimicrob Chemother. 1999;43(suppl B):1–11.

    Article  PubMed  CAS  Google Scholar 

  24. Pfaller MA, Jones RN, Wikler M, Von Seggern K. Geographic variation in antimicrobial resistance among respiratory pathogens from US outpatients: initial report from the RESP study of community-acquired respiratory tract infections (CARTI). Presented at the 40th Interscience Conference of Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto, Ontario, Canada. Abstract 600.

  25. Nicholson SC, Russo RL, Wikler MA. Differences in susceptibility ofS. pneumoniae isolated from patients with community-based respiratory tract infections. Presented at the 38th Annual Meeting of the Infectious Diseases Society of America; September 7–10, 2000; New Orleans, La. Abstract 200404.

  26. Ramirez J, Nguyen T-H, Tellier G, et al. Once-daily 400 mg oral gatifloxacin (GAT) vs twicedaily 500 mg oral clarithromycin (CLA) in the treatment of community-acquired pneumonia (CAP). Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26–29,1999; San Francisco, Calif. Abstract 2242.

  27. Gotfried M, Sullivan JG, Mayer H, Plouffe J. A randomized, double-blind, multicenter, comparative study of gatifloxacin vs levofloxacin in the treatment of community-acquired pneumonia. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26–29,1999; San Francisco, Calif. Abstract 2243.

  28. DeAbate CA, McIvor RA, McElvaine P, Skuba K, Pierce PR. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis.J Respir Dis. 1999;20(suppl 11):S23-S29.

    Google Scholar 

  29. López-Sisniega JA, Belalcázar V, Mascareño A, et al. Gatifloxacin in the treatment of acute bacterial sinusitis (ABS) in Mexico. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26–29,1999; San Francisco, Calif. Abstract 0166.

  30. King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics.Am Fam Physician. 2000;61:2741–2748.

    PubMed  CAS  Google Scholar 

  31. Conder ML, Lawrence JH, Levesque PC, Blanar MA. Inhibition of the HERG potassium channel by fluoroquinolone antibacterials: correlation with risk for clinically significant QT interval prolongation. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20,1999; Toronto, Ontario, Canada. Abstract 810.

Download references

Author information

Authors and Affiliations

  1. Hospital de Especialidades Miguel Hidalgo Aguascalientes, AGS, Mexico

    J. L. Casillas M.D.

  2. Centro Méedico Nacional La Raza, Hospital General Gaudencio González Garza, Mexico City, Mexico

    G. Rico M.D. & D. Rodríguez-Parga M.D.

  3. Hospital Regional del ISSSTE Culiacan, SIN, Mexico

    A. Mascareño M.D.

  4. Centro Médico Nacional Siglo XXI, Mexico City, Mexico

    S. Rangel-Frausto

Authors
  1. J. L. Casillas M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Rico M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Rodríguez-Parga M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Mascareño M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Rangel-Frausto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casillas, J.L., Rico, G., Rodríguez-Parga, D. et al. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections. Adv Therapy 17, 263–271 (2000). https://doi.org/10.1007/BF02850009

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850009

Keywords

Search

Navigation